Mesoblast (NASDAQ:MESO) Trading Up 7.3%

Mesoblast Limited (NASDAQ:MESO)’s stock price was up 7.3% on Tuesday . The company traded as high as $8.47 and last traded at $8.10. Approximately 207,907 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,112,417 shares. The stock had previously closed at $7.55.

Analyst Ratings Changes

Several analysts recently commented on MESO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research report on Thursday, June 20th. StockNews.com lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Mesoblast presently has an average rating of “Hold” and a consensus target price of $13.67.

Mesoblast Price Performance

The firm has a market capitalization of $935.12 million, a PE ratio of -7.23 and a beta of 3.48. The company’s fifty day simple moving average is $7.36 and its 200-day simple moving average is $4.88.

Hedge Funds Weigh In On Mesoblast

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chapin Davis Inc. lifted its holdings in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after purchasing an additional 5,000 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after purchasing an additional 1,663 shares in the last quarter. Perkins Coie Trust Co purchased a new position in shares of Mesoblast in the second quarter worth about $68,000. Finally, Chase Investment Counsel Corp purchased a new position in shares of Mesoblast in the first quarter worth about $298,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.